Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Writing clinical scenarios for clinical science questions.

Smith PE, Mucklow JC.

Clin Med (Lond). 2016 Apr;16(2):142-5. doi: 10.7861/clinmedicine.16-2-142. Review.

2.

TNF therapy for spondyloarthropathy: can we marshal the argument?

Dawes PT, Packham JC, Mucklow JC.

Rheumatology (Oxford). 2004 Sep;43(9):1069-71. Epub 2004 Jul 27. No abstract available.

PMID:
15280568
5.

Reporting drug safety in clinical trials: getting the emphasis right.

Mucklow JC.

Lancet. 2001 May 5;357(9266):1384. No abstract available.

PMID:
11356432
6.

How can we afford costly medicines?

Mucklow JC.

J R Coll Physicians Lond. 2000 Mar-Apr;34(2):124-7.

PMID:
10816863
7.

Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes.

Collin M, Mucklow JC.

Br J Clin Pharmacol. 1999 Aug;48(2):134-7. No abstract available.

8.

Clinical pharmacology and therapeutics in a changing world.

Mucklow JC.

J R Coll Physicians Lond. 1999 May-Jun;33(3):205-7. Review. No abstract available.

PMID:
10402564
9.

Postgraduate education in clinical pharmacology and therapeutics.

Mucklow JC.

Br J Clin Pharmacol. 1998 Apr;45(4):339-46. Review. No abstract available.

10.

Thrombolytic treatment. Streptokinase is more economical than alteplase.

Mucklow JC.

BMJ. 1995 Dec 2;311(7018):1506. No abstract available.

11.

Studies of the oral bioavailability of alendronate.

Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG.

Clin Pharmacol Ther. 1995 Sep;58(3):288-98.

PMID:
7554702
13.

A rapid bioassay technique for arginine-vasopressin.

Hirji MR, Mucklow JC.

Biochem Soc Trans. 1991 Apr;19(2):124S. No abstract available.

PMID:
1909654
14.

A single oral dose method for predicting steady state theophylline concentrations in clinical practice.

Mann JS, Fitzpatrick RW, Jones PW, Prowse K, Mucklow JC, Cole RB.

Respir Med. 1990 Nov;84(6):479-84.

PMID:
2274687
15.

Perceptions of pain relief after surgery.

Kuhn S, Cooke K, Collins M, Jones JM, Mucklow JC.

BMJ. 1990 Jun 30;300(6741):1687-90.

16.

Environmental factors affecting drug metabolism.

Mucklow JC.

Pharmacol Ther. 1988;36(1):105-17. Review. No abstract available.

PMID:
3277207
17.

The effects of diabetes mellitus, exercise, and single doses of biguanides upon lactate metabolism in man.

Fletcher P, Hirji MR, Kuhn S, Alexander L, Mucklow JC.

Br J Clin Pharmacol. 1986 Jun;21(6):691-9.

18.

The fate of drugs in pregnancy.

Mucklow JC.

Clin Obstet Gynaecol. 1986 Jun;13(2):161-75. Review.

PMID:
2873913
20.

Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health.

Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG.

Br J Clin Pharmacol. 1985 Nov;20(5):500-2.

21.

A comparative study of the bioavailability of five different phenytoin preparations.

Hirji MR, Measuria H, Kuhn S, Mucklow JC.

J Pharm Pharmacol. 1985 Aug;37(8):570-2.

PMID:
2864420
22.

Clinical pharmacology in practice.

Pearson RM, Mucklow JC.

J R Coll Physicians Lond. 1984 Oct;18(4):219-21. No abstract available.

23.

Partial reversal of carbamazepine-induced water intolerance by demeclocycline.

Ballardie FW, Mucklow JC.

Br J Clin Pharmacol. 1984 Jun;17(6):763-5.

25.

Acetylator phenotype and the effect of dapsone in rheumatoid arthritis.

Crook PR, Hortas C, Roberts EJ, Swinson DR, Mucklow JC, Shadforth MF.

J Rheumatol. 1983 Oct;10(5):805-8.

PMID:
6644705
26.

Benzodiazepine withdrawal in general practice.

Hopkins DR, Sethi KB, Mucklow JC.

J R Coll Gen Pract. 1982 Dec;32(245):758-62.

27.

N-acetylation phenotype in bladder cancer.

Woodhouse KW, Adams PC, Clothier A, Mucklow JC, Rawlins MD.

Hum Toxicol. 1982 Oct;1(4):443-5.

PMID:
7173929
28.

Clinical pharmacology in the Health Service: a progress report.

Mucklow JC, Bennett PN.

Health Trends. 1982 Aug;14(3):60-3. No abstract available.

PMID:
10258585
29.
30.

The relationship between individual dietary constituents and antipyrine metabolism in Indo-Pakistani immigrants to Britain.

Mucklow JC, Caraher MT, Henderson DB, Chapman PH, Roberts DF, Rawlins MD.

Br J Clin Pharmacol. 1982 Apr;13(4):481-6.

31.

Family study of antipyrine clearance.

Blain PG, Mucklow JC, Wood P, Roberts DF, Rawlins MD.

Br Med J (Clin Res Ed). 1982 Jan 16;284(6310):150-2.

32.

Pharmacokinetics of phenytoin in children.

Blain PG, Mucklow JC, Bacon CJ, Rawlins MD.

Br J Clin Pharmacol. 1981 Nov;12(5):659-61.

33.

Placebo-controlled study of phenobarbitone and phenytoin in the prophylaxis of febrile convulsions.

Bacon CJ, Hierons AM, Mucklow JC, Webb JK, Rawlins MD, Weightman D.

Lancet. 1981 Sep 19;2(8247):600-4.

PMID:
6116084
34.

Monitoring of phenobarbitone and phenytoin therapy in small children by salivary samples.

Mucklow JC, Bacon CJ, Hierons AM, Webb JK, Rawlins MD.

Ther Drug Monit. 1981;3(3):275-7.

PMID:
7324092
35.

Drug oxidation in Asian vegetarians.

Mucklow JC, Rawlins MD, Brodie MJ, Boobis AR, Dollery CT.

Lancet. 1980 Jul 19;2(8186):151. No abstract available.

PMID:
6105323
36.

Environmental factors affecting paracetamol metabolism in London factory and office workers.

Mucklow JC, Fraser HS, Bulpitt CJ, Kahn C, Mould G, Dollery CT.

Br J Clin Pharmacol. 1980 Jul;10(1):67-74.

37.

The effects of age and smoking upon antipyrine metabolism.

Mucklow JC, Fraser HS.

Br J Clin Pharmacol. 1980 Jun;9(6):613-4. No abstract available.

38.

Acetanilide pharmacokinetics in kwashiorkor.

Buchanan N, Davis MD, Henderson DB, Mucklow JC, Rawlins MD.

Br J Clin Pharmacol. 1980 May;9(5):525-6. No abstract available.

39.

Antipyrene clearance in Indian villagers.

Desai NK, Sheth UK, Mucklow JC, Fraser HS, Bulpitt CJ, Jones SW, Dollery CT.

Br J Clin Pharmacol. 1980 Apr;9(4):387-94.

40.

The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine.

Mucklow JC, Caraher MT, Idle JR, Rawlins MD, Sloan T, Smith RL, Wood P.

Br J Clin Pharmacol. 1980 Mar;9(3):283P. No abstract available.

41.

4-Hydroxylation of debrisoquine in psoriasis [proceedings].

Chapman PH, Idle JR, Mahgoub A, Mucklow JC, Rawlins MD, Rogers S, Shuster S, Smith RL.

Br J Clin Pharmacol. 1980 Jan;9(1):113P-114P. No abstract available.

42.

Reduction of circulating 25-hydroxyvitamin D by antipyrine.

Wilmana PF, Brodie MJ, Mucklow JC, Fraser HS, Toverud EL, Davies DS, Dollery CT, Hillyard CJ, Macintyre I, Park BK.

Br J Clin Pharmacol. 1979 Dec;8(6):523-8.

43.

Drugs for epilepsy.

Mucklow JC, Smith DF.

Br Med J. 1979 Jul 14;2(6182):132. No abstract available.

44.

Clinical pharmacology in the NHS.

Bennett PN, Mucklow JC.

J R Soc Med. 1979 Jul;72(7):541. No abstract available.

45.

Compliance with prescribed medicines: a study of elderly patients in the community.

Wandless I, Mucklow JC, Smith A, Prudham D.

J R Coll Gen Pract. 1979 Jul;29(204):391-6.

46.

Blood pressure and plasma noradrenaline during single high-dose beta adrenoceptor blockade.

Maling TJ, Ferrara A, Mucklow JC, Reid JL, Hamilton CA, Dollery CT.

Eur J Clin Pharmacol. 1979 Jul;15(6):375-9.

PMID:
40797
47.

Compliance with drug treatment.

Smith A, Mucklow JC, Wandless I.

Br Med J. 1979 May 19;1(6174):1335-6. No abstract available.

48.

Epilepsy.

Smith DF, Mucklow JC.

Br Med J. 1979 Apr 14;1(6169):1000. No abstract available.

49.

The effect of individual dietary constituents on antipyrine clearance in Asian immigrants [proceedings].

Mucklow JC, Caraher MT, Henderson DB, Rawlins MD.

Br J Clin Pharmacol. 1979 Apr;7(4):416P-417P. No abstract available.

50.

Atenolol and chlorthalidone in combination for hypertension.

Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT.

Br J Clin Pharmacol. 1979 Apr;7(4):357-63.

Supplemental Content

Loading ...
Support Center